MedMira (MedMira) EBIT per Share : $-0.00 (TTM As of Jan. 2024)

View and export this data going back to . Start your Free Trial

What is MedMira EBIT per Share?

MedMira's EBIT per Share for the three months ended in Jan. 2024 was $0.00. Its EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2024 was $-0.00.

During the past 3 years, the average EBIT per Share Growth Rate was -14.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MedMira's EBIT per Share or its related term are showing as below:

MMIRF' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -14.5 Med: 20.6 Max: 42
Current: -14.5

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of MedMira was 42.00% per year. The lowest was -14.50% per year. And the median was 20.60% per year.

MMIRF's 3-Year EBIT Growth Rate is ranked worse than
70.18% of 1311 companies
in the Biotechnology industry
Industry Median: 3.7 vs MMIRF: -14.50

MedMira's EBIT for the three months ended in Jan. 2024 was $-0.27 Mil.

MedMira EBIT per Share Historical Data

The historical data trend for MedMira's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira EBIT per Share Chart

MedMira Annual Data

Trend

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

EBIT per Share

Get a 7-Day Free Trial

MedMira Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
EBIT per Share	Get a 7-Day Free Trial															-	-	-	-	-

MedMira EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MedMira's EBIT per Share for the fiscal year that ended in Jul. 2023 is calculated as

	EBIT per Share		(A: Jul. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-1.355	/	697.446
=	-0.00

MedMira's EBIT per Share for the quarter that ended in Jan. 2024 is calculated as

	EBIT per Share		(Q: Jan. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.274	/	698.088
=	-0.00

EBIT per Share for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00

MedMira (OTCPK:MMIRF) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MedMira EBIT per Share Related Terms

Thank you for viewing the detailed overview of MedMira's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MedMira (MedMira) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

47M:Germany MIR:Canada

Address

155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3

Website

https://www.medmira.com

MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.